Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences.

Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences, Inc . Applications have also been submitted to the next other Concerned Member States in the European Union: Austria, France, Germany, Italy, Portugal and Spain. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das’This MAA submission closely follows the submission of our NDA to the U.S.

The primary efficacy end-point of the study was change from baseline in PANSS Excited Component score , measured at two hours following the first dose of study medication. Outcomes of the study demonstrated that AZ-004 provided a statistically significant reduction in agitation compared to placebo, as assessed by the primary and important secondary end-points. We are very happy to have this Phase 3 clinical trial released in a peer-reviewed journal of the caliber of the British Journal of Psychiatry, stated Dr. James V. Cassella, Alexza Senior Vice President, Research and Development.S. In July of the yr and the submission of the MAA in Europe in the 3rd quarter.